Nurix Therapeutics, Inc. Common stock
Follow $NRIX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NRIX by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is NRIX moving today?
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
NRIX overview
Related filings and maps
Congress activity in NRIX
No receipt-qualified Congressional disclosure is present for NRIX in the cached public ledger.
NRIX contract awards, year to date.
Public federal awards linked to this ticker.
NRIX lobbying filings, year to date.
Registered lobbying filings matched to Nurix Therapeutics, Inc. Common stock.